C
ardiomyocytes challenged with increased hemodynamic load or neurohormonal stress respond by hypertrophying. A better understanding of the mechanisms that transduce hypertrophy has implications for developing strategies that can prevent functional decompensation. One important signal transducer for development and decompensation of pressure overload cardiac hypertrophy has been determined to be G␣q, the ␣-subunit of the Gq heterotrimeric G protein. 1, 2 Coupled to phospholipase C, G␣q is the common signal transducer for multiple heptahelical cardiomyocyte receptors that stimulate cardiomyocyte hypertrophy, such as angiotensin II, endothelin, ␣-adrenergic agonists, and prostaglandin F2␣. [3] [4] [5] [6] In vivo genetically manipulated mouse models demonstrate that G␣q signaling is both necessary and sufficient for pressure overload hypertrophy, 2, 7, 8 and some critical downstream mediators have been defined. 9 Activated by G␣q through phospholipase C, the protein kinase C (PKC) family of ubiquitous serine-threonine kinases has long been implicated in cardiac hypertrophy and, more recently, human heart failure. 10 The superfamily of twelve PKC isoforms is divided into three subfamilies based on functional and structural characteristics 11, 12 : "conventional" PKCs (cPKC), which include PKC␣, ␤I, ␤II, and ␥, require both calcium and phospholipid for activation, whereas "novel" PKCs (nPKC), which include PKC␦ and ⑀, require phospholipid, but not calcium (atypical PKCs are activated by phosphatidyl serine, and may represent a separate class altogether). Global knockouts of individual PKC isoforms have generally failed to define critical cardiac functions (likely due to opportunistic compensation by related isoforms [13] [14] [15] [16] ), whereas overexpression or activation of PKC isoforms has demonstrated that PKC␤, ⑀, and ␦ can each stimulate cardiac hypertrophic phenotypes. 1, [17] [18] [19] [20] [21] PKC␣ has yet to be examined as a mediator of cardiac hypertrophy or failure by either in vivo gain-or loss-of-cardiac-specific function approaches, despite being the most abundant isoform in myocardium, in vitro evidence that it can regulate cardiac myocyte growth, 22 and its regulation in human and experimental heart failure. 7, 10, 23 We analyzed the effects of myocardial PKC␣ activity utilizing novel transgenic mice expressing positive and negative regulators of cPKC translocation. Although these peptides are not specific for PKC␣, its abundance relative to other cPKCs in adult mouse heart (Ͼ80% of myocardial cPKC) resulted in a biochemical phenotype of PKC␣ gain and loss of function. We demonstrate that activation of PKC␣ had no effect on hypertrophy. Instead, PKC␣ activation diminished myocardial responsiveness to ␤-adrenergic receptor agonists, whereas PKC␣ inhibition enhanced ␤-adrenergic responsiveness. In the context of G␣q-mediated hypertrophy and upregulated PKC␣, 7, 23 further PKC␣ translocation/activation caused a restrictive cardiomyopathy and premature lethality from fulminant heart failure. G␣q mice carrying a cPKC inhibitory peptide had modestly improved cardiac function and normal longevity. These observations establish pathological effects of PKC␣ in the adult heart.
Materials and Methods

Generation of Transgenic Mice With Altered PKC␣ Translocation
Transgenic mice were generated using the cardiomyocyte-specific ␣-myosin heavy chain (MHC) promoter to express single and concatamerized (three copies) peptides corresponding to either the PKC␤C2-C4 region (cPKC inhibitor, amino acids 218 through 226 of rat PKC␤II; inhibits translocation of all cPKC isoforms) or homologous regions of PKC␤ and RACK1 (cPKC activator, enhances translocation of all cPKC isoforms) 24 (see Figure 1A , bottom). Founders were identified by genomic Southern analysis of tail clip DNA. Animals were treated in accordance with approved University of Cincinnati IACUC protocols.
Immunoblot Analysis
Quantitative immunoblot analysis of PKC isoform content used human recombinant PKC isoforms (Sigma) for generation of standard curves. 23 PKC isoform partitioning in subcellular fractions was assayed in cytosolic (100 000g supernatant) and Triton X-100 -extracted membrane (100 000g pellet) ventricular fractions sizeseparated on 10% SDS-PAGE gels. Proteins were visualized using enhanced chemifluorescence and quantitated using a Storm PhosphorImager. Antibodies for PKC␣, ␤I, ␤II, ␥, ␦, and ⑀ were obtained from Transduction Laboratories.
Functional Assessments
Two-dimensional guided M-mode echocardiography of conscious unsedated mice was used to measure left ventricular (LV) diastolic and systolic dimensions (LVEDD and LVESD) and septal and posterior wall thickness (SWT and PWT), from which fractional shortening (FS) and LV mass were derived. Pulsed wave Doppler was used to measure aortic ejection time (ET) and calculate velocity of circumferential shortening, Vcf (FS/ET). Diastolic transmitral inflow Doppler indices included the following: peak E wave velocity, peak A wave velocity, E wave deceleration time, and isovolumic relaxation time (IVRT). Invasive hemodynamic studies were performed on anesthetized, spontaneously breathing 6-to 10-week-old transgenic mice, and their nontransgenic littermate controls as described. 7 ␤AR Density and Adenylyl Cyclase Activity ␤AR density (fmol/mg) was assayed by 125-I-cyanopindolol (CYP) binding, with nonspecific binding determined with 1 mol/L alprenolol. Adenylyl cyclase activities were determined from membrane preparations as described. 7 Reactions were performed for 10 minutes at 37°C with various concentrations of isoproterenol, 10 nmol/L NaF, or 100 mol/L forskolin. Adenylyl cyclase activities are reported as pmol/min per milligram and as a unitless value after normalization to NaF and forskolin stimulation.
Isolation of Ventricular Myocytes and Electrophysiology
Cardiomyocytes were enzymatically dissociated from ventricles of 4-month-old nontransgenic (NTG) and transgenic mice. Current recordings were obtained in the whole-cell, voltage-clamp configuration of the patch-clamp technique by using 1.60 OD borosilicate glass electrodes (Garner Glass Company), essentially as described. 20 Cell capacitance was calculated by integrating the area under an uncompensated capacity transient elicited by a 25-mV hyperpolarizing test pulse (25 ms) from a holding potential of 0 mV.
Implantable Telemetry
Mice were anesthetized and underwent sterile implantation of radio telemetry devices (Data Science Incorporated). Continuous nontethered telemetry was recorded as streaming data to a dedicated computer hard drive for off-line analysis.
Histopathology, Immunohistochemistry, and Apoptosis Studies
Histological examination was performed on formalin-fixed Masson's trichrome-stained sections. Collagen content of the extracellular matrix was assessed using picrosirius red staining and Image-Pro Plus software (Media Cybernetics). Apoptosis was measured using a TUNEL assay (Promega) imaged on a dual laser Nikon PCM2000 confocal system and a Nikon Eclipse E800 microscope using an emission wavelength of 515Ϯ30 nm (fluorescein).
Statistical Analysis
Results are presented as meanϮSEM. Experimental groups were compared using Student's t test or one-way ANOVA. A Bonferroni or Newman-Keuls test was applied to all significant ANOVA results using SigmaStat software. A value of PϽ0.05 was considered significant.
Results
Effects of Cardiac-Specific cPKC Activator and Inhibitor Peptide Expression on In Vivo PKC Isoform Expression and Activation
Based on our prior experience with in vivo myocardial expression of translocation modifiers for PKC␦ and PKC⑀, 20, 21, [25] [26] [27] we initially generated multiple lines of mice expressing FLAG-epitope tagged cPKC activator and inhibitor peptides. In none of these mice was there detectable modulation of any PKC isoform translocation, nor was there any demonstrable molecular or physiological phenotype (data not shown). Confocal analysis of myocardial samples failed to demonstrate expression of the epitope-tagged peptides, despite abundant mRNA expression (data not shown), suggesting that the small peptides might be unstable. Therefore, the transgenic constructs were reengineered to express thriceconcatamerized versions of the peptides ( Figure 1A ) and reinjected. Multiple founders were identified for cPKC activator and cPKC inhibitor constructs, and three viable lines were established and phenotyped for each. As transgene expression, PKC translocation, and basal phenotype were similar between lines, baseline data (Table 1) were combined. All other data are from one each cPKC activator and inhibitor line.
Because the PKC␤-derived peptides had the potential to target any conventional PKC isoform, 24 we performed quantitative analysis of relative PKC isoform expression in adult FVB/N mouse hearts to determine the most abundant target. As shown in Figure 1B , and consistent with prior reports, 23, 28 PKC␣ was the most abundant ventricular isoform, followed by PKC␦. Of the cPKCs, besides PKC␣, only PKC␤I was measurable.
The concatamerized cPKC translocation-modifying peptides had the anticipated effects on PKC␣ subcellular partitioning, without measurable effects on PKC␤I or other isoforms (likely due to low expression of the other cPKCs in ventricular tissue; Figure 1C ). Compared with nontransgenic controls, basal PKC␣ translocation in cPKC activator hearts, measured by the ratio of immunoreactive partitioning to a particulate subcellular fraction, was increased 44Ϯ1.5% (nϭ8, Pϭ0.013 versus NTG), whereas in cPKC inhibitor hearts, it was decreased by 25Ϯ2.6% (nϭ8, Pϭ0.043 versus NTG). This degree of basal translocation modification is somewhat greater than the 15% to 20% values for our previously described PKC␦ and ⑀ translocation modifier mice. 21, 27 PKC␣, PKC␤1, and PKC⑀ content were not altered in the transgenic mouse hearts (data not shown).
PKC␣ Translocation Enhancement Is Not Sufficient to Cause Cardiac Hypertrophy In Vivo
Multiple lines of transgenic mice expressing either the cPKC activator or inhibitor peptides were outwardly normal and healthy in all respects. Gross chamber geometry and dimensions ( Figure 2A and Table 1 ), and histological appearance (not shown) were normal. Despite the previously noted association between PKC␣ upregulation and cardiac hypertrophy in the G␣q mouse and other pathological cardiac states, 7,10,23 and a prior report that PKC␣ expression causes hypertrophy in cardiac myocytes, 22 chronically enhanced PKC␣ translocation did not increase gravimetric cardiac mass ( Figure 2B ), echocardiographically estimated left ventricular mass (Table 1) , or isolated myocyte capacitance (Table 1) in mice followed up to 1 year. Although there was no cardiac or cardiomyocyte hypertrophy, enhanced translocation of PKC␣ caused a subtle increase in expression of some fetal cardiac genes that are upregulated in myocardial hypertrophy: Compared with normal controls, ␤MHC mRNA was increased Ϸ25 fold in cPKC activator hearts, and ANF mRNA was increased Ϸ4 fold ( Figures 2C and 2D) .
As with PKC␣ activation, PKC␣ inhibition failed to cause measurable cardiac or cardiomyocyte hypertrophy, but was associated with a Ϸ6 fold increase in ␤MHC mRNA ( Figures  2C and 2D) . ANF gene expression, thought to be a marker of cardiac failure rather and possibly of hypertrophy, 29 was not increased by chronic PKC␣ inhibition.
Functional Consequences of Myocardial PKC␣ Translocation Modulation
Consistent with the absence of any overt signs of heart failure in cPKC activator and inhibitor mice, there was also no increase in lung/body weight ratios (Table 1 ). There were no differences in basal left ventricular systolic function (measured as fractional shorting and Vcf) between either of the cPKC translocation modifier mice and their NTG littermates at 10 weeks (see Table 1 ) or 6 months. cPKC activator mice did, however, develop mild echocardiographic left ventricular dysfunction at 1 year of age (Table 1 ; PϽ0.001). Together with increased ANF gene expression in these mice, the time-dependent decrease in left ventricular ejection performance suggested that a subthreshold contractile abnormality could be caused by chronic cPKC activation. Notably, cPKC inhibitor mice retained normal ventricular function through 1 year of age (Table 1) . 
PKC␣ Activation Impairs ␤AR Responsiveness
The functional integrity of the cardiac ␤-adrenergic receptor (␤AR) system was assessed in closed chest homodynamic studies of 10-to 12-week-old mice at baseline and during dobutamine infusion. (We typically use dobutamine as the ␤1AR provides the majority of inotropic drive in the mouse heart. 30 ) Consistent with the echocardiographic findings, basal left ventricular contractile function of PKC␣ activator or inhibitor mice did not differ from nontransgenic controls ( Figure 3A) . However, responsiveness to ␤1AR stimulation was diminished in cPKC activator mice, with a rightward shift in the dobutamine-response curve ( Figure 3A Figure 3D ). Even in the context of a Ϸ30-fold increase in ␤AR receptor number, ␤AR coupling was similarly and reciprocally modulated by the cPKC translocation modifying peptides ( Figure 3D ), consistent with a potent direct effect of PKC␣ on ␤AR coupling.
Lethal Effects of PKC␣ Activation in G␣q-Mediated Hypertrophy
Although the phenotype was relatively subtle by comparison, there were intriguing similarities between the cPKC activator mice and the G␣q mice, in which PKC␣ is upregulated and activated. 7, 23 Both mice exhibit a time-dependent decrease in ventricular function associated with lack of responsiveness to ␤AR agonists and an increase in ANF and ␤MHC gene expression. However, the cPKC activator mouse has no evidence of hypertrophy, which is the hallmark characteristic of G␣q activation in the heart. This suggested that the major function of PKC␣ activation could be to regulate cardiac function, rather than myotrophy. To test whether concurrent G␣q-mediated events would unmask a more significant effect of PKC␣ modulation, we expressed both cPKC translocation modifier peptides on the G␣q overexpressor background, analogous to our prior studies of G␣q in combination with PKC⑀ translocation modifiers. 25 Our expectation was that the relatively subtle deleterious effects observed with enhanced PKC␣ translocation might be augmented in the context of G␣q-mediated myocardial hypertrophy, whereas PKC␣ inhibition might prevent some G␣q-mediated pathological effects. The combination of G␣q and the cPKC inhibitor peptide in compound transgenic mice resulted in animals with normal viability and molecular characteristics essentially identical to the parent G␣q mouse (Figures 4A and 4B) . Compared with G␣q, G␣q/cPKC inhibitor mice had modest, but significantly smaller hearts, measured as heart weight indexed to body weight (Table 2) . A contrasting phenotype was observed in the compound G␣q/cPKC activator mice, which displayed stunted growth and premature lethality compared with G␣q mice (Table 2, Figure  4C ), accompanied by increased heart to body weight ratios (Table 2) . Additionally, expression of embryonic cardiac genes was exaggerated compared with G␣q alone ( Figures   4A and 4B) . It was not possible to obtain an unbiased assessment of ventricular function in the G␣q/cPKC activator compound transgenics because all male compound transgenic mice died by the age of 5 weeks ( Figure 4C ). Ventricular tachyarrhythmia was ruled out as the proximate cause of death in these mice, because chronic telemetered EKG monitoring showed only progressive bradycardia and high grade AV block that coincided with tachypnea and lethargy, suggesting that the mice succumbed to heart failure ( Figure 4D) . Indeed, at 4 weeks of age, male G␣q/cPKC activator mice exhibited a substantial decline in LV shortening velocity and depressed heart rate, compared with G␣q alone (Table 2) , which along with stunted growth (Table 2) , are common features of heart failure in juvenile mice. 34 Although aggressive heart failure in male compound G␣q/ cPKC activator mice precluded a careful assessment of physiological cause and mechanism, we were able to investigate events preceding lethality by studying the females, who exhibited a slower progression of heart failure, dying by 13 weeks of age ( Figure 4C ). (Similar gender separation has been described in other transgenic mouse heart failure models. 35 weight ratios in the compound transgenic G␣q/cPKC activator mice (G␣q 7.83Ϯ0.39 versus G␣q/cPKC activator 10.41Ϯ1.38; Pϭ0.027).
The disparity between progressive heart failure and relatively preserved ventricular dimension and systolic function, ie, the absence of characteristic ventricular dilation measured either by echocardiography or by gross morphometric analysis (see Table 2 and Figure 5 ), suggested that diastolic functional abnormalities could contribute to lethal heart failure. Fortunately, the inherent bradycardia of G␣q mice permitted interrogation of transmitral inflow Doppler patterns for characteristic abnormalities associated with diastolic dysfunction. Compared with G␣q, G␣q/cPKC activator mice had higher peak E wave velocities with significantly shorter E wave deceleration times ( Figure 4E ; G␣q, 35.02Ϯ3.01 ms versus G␣q/cPKC activator, 18.02Ϯ2.0; Pϭ0.022), reflecting increased left atrial pressures and impaired ventricular filling. These animals completely lacked an A wave, indicating atrial mechanical failure that correlated with extensive atrial thrombosis seen in almost every heart ( Figures 5C and  5D ). Consistent with these noninvasive studies, invasive hemodynamics revealed that G␣q/cPKC activator mice had diminished positive and negative dP/dt, and increased left ventricular end-diastolic pressures (LVEDP), compared with G␣q (Table 2) . (In contrast, G␣q/cPKC inhibitor mice had a modest, but significant improvement in both systolic and diastolic function, measured by positive and negative dP/dt, respectively [ Table 2 ].) Because the above diastolic parameters are relatively load-dependent, we performed pressure-dimension analysis to determine the compliance curves of each ventricle. G␣q/cPKC activator mice had a significant left and upward shift in compliance curves, compared with G␣q (slope constant G␣q, 13.04Ϯ1.4 versus G␣q/cPKC, 30.1Ϯ1.9; Pϭ0.017), representing increased ventricular stiffness.
Although there were no differences in TUNEL positivity (G␣q 0.36Ϯ0.12% versus G␣q/cPKC activator 0.55Ϯ0.08%), a cellular mechanism for combined systolic and diastolic failure in compound transgenic G␣q/cPKC activator mice was identified: Masson's Trichrome staining revealed marked interstitial fibrosis (Figures 5A through 5D ) and staining with picrosirius red showed Ϸ4-fold increased interstitial collagen content in the G␣q/cPKC activator mice, compared with normal, and Ϸ2-fold increased compared with G␣q ( Figure  6 ). G␣q/cPKC inhibitor mice had the reciprocal finding of decreased collagen deposition fraction (Figure 6 ). 
Discussion
To our knowledge, these are the first studies to examine forced gain or loss of PKC␣ function in the in vivo heart. As with our previous studies of PKC␦ and ⑀, 20, 21, 26, 27 the approach was to modify PKC isoform activity by positively or negatively modulating translocation. In contrast to these prior studies, the PKC␤-derived peptides used herein lack absolute specificity for the targeted enzyme, but had the potential to modulate translocation of PKC␣, ␤, and ␥. 19 However, that adult FVB/N mouse hearts contained vastly more PKC␣ than PKC␤I, PKC␤II, or PKC␥, and the biochemical phenotype was therefore that of PKC␣ regulation, with no measurable effects on other PKC isoforms. Nevertheless, the conclusions regarding in vivo PKC␣ effects will need to be confirmed by standard transgenic and knockout studies. In this context, our results suggest that isolated alterations of myocardial PKC␣ activity can modulate ␤AR coupling, and hence contractile function, in the heart. Additionally, PKC␣ appears to mediate interstitial fibrosis and restrictive ventricular physiology. Indeed, in our studies, inhibiting PKC␣ translocation in G␣q-mediated hypertrophy might be viewed as conferring a modest therapeutic benefit. In vitro studies have previously implicated PKC-mediated phosphorylation in regulating ␤AR receptors. 31, 32 The reciprocal effects observed herein on ␤AR response with PKC␣ activating and inhibiting peptides, and the absence of similar ␤AR regulation in analogous models targeting PKC␦ and ⑀ 20,21,26,27 suggest that the ␣ isoform of PKC can be an important modulator of ␤AR responsiveness in the heart. Whereas inhibition of PKC␣ enhanced ␤AR-mediated inotropic responsiveness to infused dobutamine, activation of PKC␣ resulted in ␤AR uncoupling in young mice that was associated with overt basal contractile dysfunction at 1 year of age. Importantly, these effects were independent of cardiac hypertrophy and failure, and thus do not represent actions of endogenous catecholamines. Although the association is correlative only, it suggests the possibility that chronic ␤AR uncoupling can be deleterious in the normal heart.
In the present study, myocardial fibrosis and restrictive physiology were related to PKC␣ activation only in the context of G␣q-mediated hypertrophy and contractile dysfunction. Myocardial fibrosis is a hallmark of heart failure in human and experimental models, and contributes to functional decompensation because accumulation of interstitial collagen stiffens the ventricle, impairing both systolic and diastolic function. 36, 37 A physiological connection between PKC and fibrosis is found in the angiotensin system. Yazaki has suggested that angiotensin stimulates cardiomyocytes via G␣q/PKC/ERK signaling 38 and lack of AT-2 receptors prevents both hypertrophy and myocardial fibrosis in angiotensin-induced hypertension. 39 We found increased levels of phosphorylated ERK in cPKC activator hearts (data not shown), confirming the integrity of this signaling pathway in the in vivo heart, and suggesting for the first time a causal relationship between myocyte PKC␣ activity and development of myocardial fibrosis. Furthermore, the nature of the fibrosis observed in G␣q/activator mouse hearts was "reactive" or interstitial, which is not associated with cell death, as opposed to "reparative" or replacement fibrosis, which is the scarring that typically follows cell death. An unresolved issue that arises from these observations is how a cardiomyocyte-specific signaling perturbation can result in increase interstitial collagen, which is presumably synthesized not by cardiomyocytes, but by fibroblasts. Again the angiotensin system provides a compelling example. Ichikawa generated chimeric mice with both intact and AT-1 receptor null cells, 40 in which infusion of angiotensin caused fibroblast proliferation clustered around the AT-1-expressing cardiac myocytes, providing evidence for local myocyte-to-fibroblast communication. Thus, altered myocyte signaling can contribute to ventricular remodeling through communication with fibroblasts and resulting myocardial fibrosis.
It is useful to compare the results of the current investigations with prior attempts to delineate the roles of PKC isoforms using the approach of translocation modification. PKC⑀ seemed to primarily have trophic functions, because its activation produced hyperplastic cardiac enlargement, 20, 27 and its inhibition cause a hypoplastic dilated cardiomyopathy. 20 Increasing PKC⑀ activity in the G␣q mouse reversed some of the pathological features of that model. 25 Thus, PKC⑀ seems to be a beneficial isoform, which is supported by conventional transgenic overexpression studies. 19 In contrast, modulated translocation of PKC␦ had little measurable effect on myocardial growth or function, but was critical to maintaining proper cytoskeletal structure in cardiac myocytes. 26 Activation of PKC␦, like PKC⑀, resulted in modest, normally functioning cardiomegaly, whereas its inhibition produced a cytoskeletal cardiomyopathy. These results contrast with those for PKC␣, which seems to affect cardiac function more than growth, notwithstanding in vitro studies that suggested a trophic function. 22 Whereas PKC␣ is the most abundant conventional PKC isoform in the adult FVB/N mouse heart (vide supra), PKC␤ is the major cPKC isoform in human myocardium. Indeed, substantial evidence exists that PKC␤ mediates certain pathological aspects of human cardiac hypertrophy and heart failure. PKC␤ expression and activity is increased in human heart failure. 10 Expression of PKC␤ in the mouse heart (more an ectopic expression experiment than overexpression) results in hypertrophy, failure, and death, depending on the age of expression and the activity of the expressed enzyme. 17, 18 It is interesting to speculate that PKC␣ in the mouse heart has many of the same effects as PKC␤ in the human, which suggests that cPKC isoforms may be generally pathological in the heart. In summary, these studies demonstrate that PKC␣ can have profound modulatory effects on cardiac contractility by regulating ␤-adrenergic receptors. In the context of G␣q-mediated cardiac hypertrophy, PKC␣ appears to stimulate reactive fibrosis, thereby impairing both systolic and diastolic function, and leading to early heart failure and premature lethality. These results suggest that conventional PKC isoforms may be useful therapeutic targets in heart failure syndromes.
